Tenderwize
Retour à la recherche

Non-exclusive discount agreement for sodium oxybate

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Nov 30, 2027 · 459 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Natriumoxybat (ATC-Code nach WHO: N07XX04)

20/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

20 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed quantities; actual revenue depends on unknown prescription volumes.

The contracting authority may terminate the Open-House process early if exclusive discount agreements are concluded.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Conclusion of non-exclusive discount agreements for sodium oxybate (ATC N07XX04)
  • Open-House model: any qualifying pharmaceutical entrepreneur can participate
Afficher le résumé complet

This tender is a non-exclusive discount agreement (Rabattvereinbarung) under § 130a Abs. 8 SGB V for the active substance sodium oxybate (ATC N07XX04) using an Open-House model. The contracting authority is AOK PLUS for the states of Saxony and Thuringia. Participation is open to all interested pharmaceutical entrepreneurs meeting eligibility criteria. No individual negotiations, no exclusivity, and no guaranteed purchase volumes. The framework ends on 30.11.2027. Submissions are electronic via DTVP portal. First submission deadline is 04.11.2025, with further rolling deadlines.

Risques

No guaranteed quantities; actual revenue depends on unknown prescription volumes.

The contracting authority may terminate the Open-House process early if exclusive discount agreements are concluded.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Participant must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG

Eligibility

  • Must submit self-declaration on absence of grounds for exclusion (according to §§ 123, 124 GWB)

Administrative

  • Must submit self-declaration on compliance with Russia sanctions (EU Regulation 833/2014)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; the procedure is based on acceptance of predefined terms.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive discount agreement for sodium oxybate

Non-exclusive discount agreement for pharmaceutical products containing sodium oxybate, under an Open-House model. No exclusivity, no minimum volumes, and no individual negotiations.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Nov 2025 - Nov 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; the procedure is based on acceptance of predefined terms.

Date limite

Deadline Nov 30, 2027

Détails de la procédure

Date de publication
17 Sep 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
609690-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30